American Century Companies’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
AIM
OAG
GP
SOCM
American Century Companies's CRSP Position: Q2 2026 in Review
American Century Companies increased its CRISPR Therapeutics (CRSP) stake by 16% in Q2 2026, buying an estimated $1M and bringing the position to 139,462 shares worth $7.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1698.
American Century Companies first reported a position in CRSP in Q1 2020 and has held it in 25 quarters since. The position peaked at $61M in Q2 2021. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.
- American Century Companies held 139,462 shares of CRISPR Therapeutics worth $7.61M as of Q2 2026.
- American Century Companies bought 18,974 CRISPR Therapeutics shares in Q2 2026, an estimated $1M.
- CRISPR Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #1698 holding.
- American Century Companies first reported a position in CRISPR Therapeutics in Q1 2020 and has held it in 25 quarters since.
- American Century Companies's CRISPR Therapeutics position peaked at $61M in Q2 2021.
- 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.
Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.